Elsevier

Gynecologic Oncology

Volume 57, Issue 1, April 1995, Pages 96-104
Gynecologic Oncology

Regular Article
Usefulness of Immunohistochemical Staining for p53 in the Prognosis of Breast Carcinomas: Correlations with Established Prognosis Parameters and with the Proliferation Marker, MIB-1

https://doi.org/10.1006/gyno.1995.1104Get rights and content

Abstract

Mutations of the p53 gene often result in the overexpression of p53 protein. Previous studies have suggested that the function of p53 and its mutant protein forms may be linked with the disease course of patients with a breast carcinoma. In the present study, we tested 462 primary breast carcinomas for the presence of p53 antigen using immunohistochemical methods employing antibodies against the clone, DO-I. These tumors were also immunohistochemically stained using the monoclonal antibody, MIB-1, in order to demonstrate the presence of Ki67. Comparison of the presence of p53 with other prognostic parameters revealed highly significant negative correlations with estrogen- and progesterone-receptor status (P < 0.001 and P = 0.001, respectively) as well as positive correlations with both the presence of Mill-1 (P < 0.001) and the histological grading (P = 0.008). The presence of p53 was not correlated with tumor stage and node status. Evaluation of the findings for all 462 tumors as well as for node-positive and -negative subgroups revealed less favorable findings for overall survival and the disease-free period for both p53-positive tumors (for total group, overall survival, P = 0.0002, disease-free period, P = 0.02; for node-positive group, overall survival, P = 0.0004, disease-free period, P = 0.1045) and breast carcinomas with higher proportions of cell nuclei positive for MIB-1 (total, overall survival, P = 0.0026, disease-free period, P = 0.0022; node-positive, overall survival, P = 0.021, disease-free period, P = 0.0882). We were able to demonstrate that p53 expression in breast carcinomas means a significantly worse prognosis for grade II tumors (overall survival, P = 0.0002; disease-free period, P = 0.0116), for overall survival in the case of estrogen-receptor-positive tumors (P = 0.014), and for tumors showing increased proliferation activity (overall survival, P = 0.0477).

References (0)

Cited by (53)

  • Breast Cancer Biomarkers

    2005, Advances in Clinical Chemistry
    Citation Excerpt :

    In general, breast carcinomas with p53 mutations are associated with high histologic grade, high mitotic index, high cell proliferation rate, aneuploid DNA content, negative assays for estrogen and progesterone receptor [46], and variable association with amplification of oncogenes such as HER‐2/neu, C‐myc, ras, and int‐2 [47]. Some (but not all) studies have implicated p53 mutation with resistance to hormonal, adjuvant, and neo‐adjuvant chemotherapy and combination chemotherapy for metastatic disease encompassing a variety of agents, including anthracyclines and taxanes [48–56]. Currently, determination of p53 status is not included as a part of the standard of practice for the management of breast cancer.

  • Identification of therapeutic targets of breast cancer

    2016, International Journal of Clinical and Experimental Medicine
  • Breast cancer statistics and markers

    2014, Journal of Cancer Research and Therapeutics
View all citing articles on Scopus
View full text